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Fig. 1. Viral kinetics according to patient’s adherence status.
Letters to the EditorTo the Editor:
We read with interest the study entitled ‘‘Persistence and adher-
ence to nucleos(t)ide analogue treatment for chronic hepatitis B’’
by Chotiyaputta et al. [1]. This study is the ﬁrst known report in
‘‘true life setting’’ of antiviral drug adherence of HBV patients.
Using the US pharmacist providing system, data were collected
from 11,100 patients taking HBV antiviral drugs. 55.3% of patients
were taking more than 90% of their medication conﬁrming that
drug adherence might be better than that observed in HIV patient
population [2,3]. This result could be explained by HBV antiviral
therapy favourable proﬁle for adherence, characterised by a once
a day medication and quality of life not altered by side effects [4].
However, authors pointed out the limitations of their ﬁndings,
particularly the absence of virological monitoring regarding
adherence status and the absence of correlation with break-
through occurrence.
Considering these limitations of Chotiyaputta’s study, we
report a series of 47 chronic hepatitis B patients either treated
solely by adefovir therapy or in addition to lamivudine, for at
least 3 years. Here, the adherence rate was assessed by a direct
method, i.e., measurement of adefovir plasma levels, and was cor-
related with the virological response.
Patients’ characteristics were as follows: median age of
48 years, 81% male, 30% HBe(+) Ag, genotypes D 51%, A 38%, 75
percent had received prior treatment with nucleoside analogues.
HBV DNA level (VL) was monitored by RT-PCR (sensitivity 12 IU/
ml) every three months. Sequencing of HBV polymerase search-
ing for known adefovir mutations (A181V, N236T and A181V/
T + N236T) was performed in case of 0.5 log IU/L VL increase.
Adefovir plasma levels were assessed by liquid chromatography
tandem mass spectrometry in serum (lower limit of quantiﬁca-
tion: 1 ng/ml) every year (Y) and every time HBV DNA level
increased by more than 0.5 log IU/ml.
14 patients (30%) had undetectable adefovir levels at least on
one occasion during total treatment period. Among them, 6 (13%)
had repeatedly undetectable adefovir levels per study observa-
tion period (one occasion n = 8, twice n = 2 and more than 2 times
n = 4). Adefovir undetectability was observed at Y1 (15%), Y2
(11%), Y3 (17%), Y4 (8%). Those patients had 2.6 fold lower serum
concentrations independently of weight on all time points from
Y1 to Y4 (7.4 vs. 19.0 lg/L, p <0.0001). These were thus considered
as being ‘‘poor adherent’’. They were signiﬁcantly younger (39 vs.
52 years, p <0.001) and subsequently more frequently HBeAg+
(57% vs. 18%) with higher viral load (7.4 vs. 6.1 log IU/ml). As
shown in Fig. 1, virological response was signiﬁcantly better in
adherent patients during the ﬁrst year of treatment. At Y1, the
mean viral load was signiﬁcantly higher for poor adherent
patients (4.37 log IU/ml vs. 2.96 log IU/ml; p = 0.001). At Y2,
patients with poor adherence were less likely to achieve unde-
tectable HBV DNA (21% vs. 42%, p <0.01), while there was a
non-signiﬁcant trend at year 4 (32% vs. 68%, p <0.07). Virological
relapse was observed in 15 patients, mainly after two years of
treatment. At the time of relapse, 9 patients demonstrated adefo-1468 Journal of Hepatology 20vir resistance mutations. 7 had undetectable adefovir levels, 2
patients only showing resistance mutation in this subgroup.
Our study demonstrates that 30% of the patients were at least
once ‘‘non adherent’’ to antiviral treatment, a scenario associated
to lower adefovir concentrations in other time points. This sug-
gests poor adherence over the treatment period. In Chotiyaputta’s
study, results were expressed in a different manner: 47% of the
patients reached an adherence rate lower than 90% and were con-
sidered as having poor adherence. The higher rate of poor adher-
ence reported in Chotiyaputta’s study could be due to
discrepancies in methods assessing adherence. Indeed, we used
a very stringent criterion of poor adherence, deﬁned by a dosage
lower than the quantiﬁcation lower limit that is certainly highly
speciﬁc for detecting adherence failure but probably less sensi-
tive than indirect methods.
We found in our series similar results to Chotiyaputta et al.
regarding the characteristics of poor adherent patients. Younger
patients, respectively 39 year-old or less than 45 year-old in
Chotiyaputta study, were less likely to have a good adherence
rate. Chotiyaputta et al. underlined the ﬁrst 6 months of therapy
as a predicting factor of poor adherence. In our study, one third of
patients had undetectable adefovir level among the ﬁrst year of
treatment. However, a linear progression of poor adherence rate
throughout the 4 years of our study must be stressed. Similarly
Chotiyaputta et al. found lamivudine as a predictor of poorer
adherence, which could be a marker of longer treatment
duration.
Complementary to Chotiyaputta’s study we clearly demon-
strate a strong link between adherence rate and virological
response. Adherence rate was a major factor for suboptimal
response, which might even be of greater impact than resistance
mutations. Regarding the current use of the new generation of11 vol. 55 j 1467–1472
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nucleos/tide analogues such as tenofovir or entecavir, with a high
genetic barrier, those conclusions enlighten the fact that assess-
ment of patient adherence to antiviral treatment has to be
addressed every time a suboptimal response is observed. In this
setting, antiviral drug dosing should then be considered as a
meaningful tool. Promoting persistence of on-therapeutic adher-
ence motivation in this life long treatment setting is fundamen-
tal. As described with other chronic diseases, especially HIV,
speciﬁc therapeutic educational programs are to be developed
after a proper assessment of the true determinants of patient
adherence.
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To the Editor:
We are delighted that Dr. Hilleret and colleagues concur with
our ﬁnding that in real life clinical practice, adherence to
nucleos(t)ide analogs for hepatitis B is less than ideal and
has a tendency to decline with time. We agree that the major
limitation of our study [1] is the inability to correlate our ﬁnd-
ings with clinical data, but utilizing a nationwide pharmacy
database enabled us to study a large number of patients in
the community that are more representative than a small
cohort of patients in a single tertiary referral center. We con-
gratulate Dr. Hilleret and colleagues in utilizing a direct mea-
sure of adherence – serum concentrations of the medication
administered, in this case adefovir. We are pleased to see that
Dr. Hilleret and colleagues demonstrated a correlation between
undetectable concentrations of adefovir in serum and lower
rate of virologic response. In a retrospective study of 148
patients receiving nucleos(t)ide analogs for chronic hepatitis B
in our clinic, we found that 39 patients had at least one viro-
logic breakthrough during a mean follow-up of 37.5 months
[2]. However, only 24 patients had genotypic resistance. Of
the 10 patients who experienced virologic breakthrough that
was not conﬁrmed on retesting, all 10 had further decrease
in serum HBV DNA and nine had undetectable HBV DNA dur-
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ing continued treatment with the same medications. Although
adherence was not assessed in that study, these data suggest
that medication non-adherence is a common cause of transient
virologic breakthrough. Our ﬁndings and those of Dr. Hilleret
and colleagues highlight the importance of counseling patients
with chronic hepatitis B receiving nucleos(t)ide analogs on
medication adherence to achieve optimal responses.
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